Enfusion, Inc. (NYSE:ENFN) Receives Average Rating of “Reduce” from Brokerages

Shares of Enfusion, Inc. (NYSE:ENFN) have been given an average rating of “Reduce” by the six research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $10.25.

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus increased their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Piper Sandler raised their price target on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday.

Insider Transactions at Enfusion

In other news, COO Neal Pawar sold 21,801 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the transaction, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 36.44% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. RiverPark Advisors LLC bought a new position in shares of Enfusion during the 2nd quarter valued at $68,000. Arizona State Retirement System bought a new position in shares of Enfusion during the second quarter valued at about $86,000. Harbor Capital Advisors Inc. increased its holdings in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after buying an additional 1,315 shares during the period. Belvedere Trading LLC bought a new stake in shares of Enfusion in the 3rd quarter valued at about $114,000. Finally, Paloma Partners Management Co purchased a new stake in Enfusion during the 3rd quarter valued at about $157,000. 81.05% of the stock is owned by hedge funds and other institutional investors.

Enfusion Stock Performance

NYSE:ENFN opened at $10.58 on Wednesday. The business’s fifty day moving average is $9.74 and its 200 day moving average is $9.02. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of 264.57, a PEG ratio of 3.98 and a beta of 0.97. Enfusion has a 52-week low of $7.52 and a 52-week high of $11.38.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.